EP2154958A4 - Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies - Google Patents
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapiesInfo
- Publication number
- EP2154958A4 EP2154958A4 EP08747605A EP08747605A EP2154958A4 EP 2154958 A4 EP2154958 A4 EP 2154958A4 EP 08747605 A EP08747605 A EP 08747605A EP 08747605 A EP08747605 A EP 08747605A EP 2154958 A4 EP2154958 A4 EP 2154958A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- spla2
- dyslipidemia
- inhibitors
- treatment
- cardiovascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91591007P | 2007-05-03 | 2007-05-03 | |
US96959107P | 2007-08-31 | 2007-08-31 | |
US87486907A | 2007-10-18 | 2007-10-18 | |
PCT/US2008/062577 WO2008137803A1 (en) | 2007-05-03 | 2008-05-02 | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2154958A1 EP2154958A1 (en) | 2010-02-24 |
EP2154958A4 true EP2154958A4 (en) | 2011-05-04 |
Family
ID=39943969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08747605A Withdrawn EP2154958A4 (en) | 2007-05-03 | 2008-05-02 | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2154958A4 (en) |
JP (1) | JP2010526152A (en) |
CN (1) | CN101742907A (en) |
AU (1) | AU2008247451A1 (en) |
BR (1) | BRPI0811486A2 (en) |
CA (1) | CA2686157A1 (en) |
EA (1) | EA200971020A1 (en) |
WO (1) | WO2008137803A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012514652A (en) * | 2009-01-08 | 2012-06-28 | アンセラ・ファーマシューティカルズ・インコーポレイテッド | Compositions and methods of secreted phospholipase A2 (SPLA2) inhibitors and niacin drugs for the treatment of cardiovascular disease and dyslipidemia |
RU2483707C1 (en) * | 2012-05-04 | 2013-06-10 | Лира Талгатовна Гильмутдинова | Method of sanatorium therapy of patients with metabolic syndrome and arterial hypertension with application of sulfide baths |
CN115040508A (en) * | 2022-07-28 | 2022-09-13 | 上海市同仁医院 | Application of indole-3-acetaldehyde in preparing novel anti-obesity active preparation |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001055108A2 (en) * | 2000-01-25 | 2001-08-02 | Eli Lilly And Company | Use of spl a2 inhibitors for the treatment of inflammation |
WO2002008189A1 (en) * | 2000-07-24 | 2002-01-31 | The University Of Queensland | Compounds and inhibitors of phospholipases |
EP1378246A1 (en) * | 2001-03-19 | 2004-01-07 | Shionogi & Co., Ltd. | Remedies for arteriosclerosis |
WO2007056281A2 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT199800127A (en) * | 1997-08-29 | 2000-02-01 | THERAPEUTIC COMBINATIONS. | |
PL344571A1 (en) * | 1998-05-01 | 2001-11-05 | Lilly Co Eli | Spla2 |
US20060094693A1 (en) * | 2004-09-21 | 2006-05-04 | Point Therapeutics, Inc. | Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions |
-
2008
- 2008-05-02 JP JP2010507578A patent/JP2010526152A/en active Pending
- 2008-05-02 CN CN200880023061A patent/CN101742907A/en active Pending
- 2008-05-02 BR BRPI0811486-2A2A patent/BRPI0811486A2/en not_active IP Right Cessation
- 2008-05-02 CA CA002686157A patent/CA2686157A1/en not_active Abandoned
- 2008-05-02 EP EP08747605A patent/EP2154958A4/en not_active Withdrawn
- 2008-05-02 AU AU2008247451A patent/AU2008247451A1/en not_active Abandoned
- 2008-05-02 WO PCT/US2008/062577 patent/WO2008137803A1/en active Application Filing
- 2008-05-02 EA EA200971020A patent/EA200971020A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001055108A2 (en) * | 2000-01-25 | 2001-08-02 | Eli Lilly And Company | Use of spl a2 inhibitors for the treatment of inflammation |
WO2002008189A1 (en) * | 2000-07-24 | 2002-01-31 | The University Of Queensland | Compounds and inhibitors of phospholipases |
EP1378246A1 (en) * | 2001-03-19 | 2004-01-07 | Shionogi & Co., Ltd. | Remedies for arteriosclerosis |
WO2007056281A2 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors |
Non-Patent Citations (7)
Title |
---|
CHEN W M ET AL: "Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A2", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 522, no. 1-3, 3 July 2002 (2002-07-03), pages 113 - 118, XP004369256, ISSN: 0014-5793, DOI: 10.1016/S0014-5793(02)02907-1 * |
MA J ET AL: "Are evidence-based cardiovascular prevention therapies being used? A review of aspirin and statin therapies", PREVENTION AND CONTROL, ELSEVIER, NL, vol. 1, no. 4, 1 December 2005 (2005-12-01), pages 285 - 295, XP025337910, ISSN: 1573-2088, [retrieved on 20051201], DOI: 10.1016/J.PRECON.2006.05.002 * |
ROBINSON JENNIFER G ET AL: "Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction", EXPERT REVIEW OF CARDIOVASCULAR THERAPY, EXPERT REVIEWS LTD, GB, vol. 4, no. 4, 1 July 2006 (2006-07-01), pages 461 - 476, XP008134541, ISSN: 1744-8344, DOI: 10.1586/14779072.4.4.461 * |
RODONDI NICOLAS ET AL: "Aspirin for the primary prevention of cardiovascular disease a comprehensive review", COMPREHENSIVE THERAPY, vol. 31, no. 3, October 2005 (2005-10-01), pages 186 - 193, XP002629623, ISSN: 0098-8243 * |
See also references of WO2008137803A1 * |
VERVOORDELDONK M J ET AL: "Aspirin inhibits expression of the interleukin-1beta-inducible group II phospholipase A2.", FEBS LETTERS 11 NOV 1996 LNKD- PUBMED:8941724, vol. 397, no. 1, 11 November 1996 (1996-11-11), pages 108 - 112, XP002629622, ISSN: 0014-5793 * |
WIKLUND O ET AL: "Effects of simvastatin and atorvastatin on inflammation markers in plasma", JOURNAL OF INTERNAL MEDICINE, vol. 251, no. 4, April 2002 (2002-04-01), pages 338 - 347, XP002629621, ISSN: 0954-6820 * |
Also Published As
Publication number | Publication date |
---|---|
CA2686157A1 (en) | 2008-11-13 |
BRPI0811486A2 (en) | 2014-09-30 |
JP2010526152A (en) | 2010-07-29 |
AU2008247451A1 (en) | 2008-11-13 |
EP2154958A1 (en) | 2010-02-24 |
WO2008137803A1 (en) | 2008-11-13 |
EA200971020A1 (en) | 2010-10-29 |
CN101742907A (en) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1218256A1 (en) | Methods of using mek inhibitors mek | |
IL240771A0 (en) | Benzoxazole kinase inhibitors and methods of use | |
IL208719A0 (en) | Inhibitors of protein kinases | |
EP2026843A4 (en) | Therapeutic uses of inhibitors of rtp801l | |
RS58965B1 (en) | Arginase inhibitors and methods of use | |
HK1160119A1 (en) | Kinase inhibitors and methods of use | |
EP2379561A4 (en) | Mlk inhibitors and methods of use | |
EP2252293A4 (en) | Kinase inhibitors and methods of use | |
EP1981888A4 (en) | Inhibitors of tyrosine kinases and uses thereof | |
HK1129387A1 (en) | Human protein-tyrosine phosphatase inhibitors and methods of use | |
IL200611A0 (en) | Inhibitors of serine proteases | |
EP2127251A4 (en) | Propagation of conflict knowledge | |
EP2007383A4 (en) | Inhibitors of protein prenyltransferases | |
IL208212A0 (en) | Hydroxamate-based inhibitors of deacetylases b | |
ZA201006353B (en) | Inhibitors of gm-csf and il-17 for therapy | |
IL201254A0 (en) | 5 - oxo - isoxazoles as inhibitors of lipases and phospholipases | |
EP2154958A4 (en) | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies | |
EP2485750A4 (en) | Peptide-based peroxidase inhibitors and methods of using same | |
EP2234493A4 (en) | Therapeutic use of carboxyl ester lipase inhibitors | |
IL201897A0 (en) | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies | |
IL212990A0 (en) | Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies | |
GB0719877D0 (en) | Inhibitors of protein kinases | |
IL195722A0 (en) | Therapeutic uses of inhibitors of rtp801l |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20091202 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1139282 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20110401 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 9/10 20060101ALI20110325BHEP Ipc: A61K 45/06 20060101ALI20110325BHEP Ipc: A61K 31/404 20060101ALI20110325BHEP Ipc: A61K 31/19 20060101ALI20110325BHEP Ipc: A01N 37/10 20060101AFI20081127BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20120829 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1139282 Country of ref document: HK |